title: [Osteoimmunology - IMMUNOBONE - Understanding the interaction between bone and immune system].
abstract: The special program "Osteoimmunology" under the leadership of the Universities of Erlangen, Jena, Gießen and Münster, is investigating in 27 projects clarification approaches on the causes of inflammatory rheumatic diseases, such as rheumatoid arthritis and ankylosing spondylitis with the aim of developing new forms of treatment. The molecular mechanisms involved in bone damage and the interaction between the immune system and bone and cartilage are topics of research.
authors.affiliation: Medizinische Klinik 3, Rheumatologie & Immunologie, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsklinikum Erlangen, Erlangen, Deutschland. georg.schett@uk-erlangen.de
authors.forename: G
authors.initials: G
authors.lastname: Schett
authors.forename: T
authors.initials: T
authors.lastname: Pap
authors.forename: U
authors.initials: U
authors.lastname: Müller-Ladner
authors.forename: T
authors.initials: T
authors.lastname: Kamradt
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000235:genetics / Q000276:immunology*; D001842:Bone and Bones / Q000276:immunology*; D002356:Cartilage / Q000276:immunology; D006801:Humans; D055261:Immunogenetic Phenomena / Q000235:genetics / Q000276:immunology; D013167:Spondylitis, Ankylosing / Q000188:drug therapy / Q000235:genetics / Q000276:immunology*; D057170:Translational Research, Biomedical; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000097:blood
chemical_list: D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha